

Noemi Reguart

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1528409/publications.pdf>

Version: 2024-02-01

123
papers

14,588
citations

44069

48
h-index

19190

118
g-index

123
all docs

123
docs citations

123
times ranked

15534
citing authors

#	ARTICLE	IF	CITATIONS
1	Spotlight on Camrelizumab in Advanced Squamous Lung Cancer: Another Feather in the Cap of Chinese Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 477-480.	1.1	2
2	Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8508-8508.	1.6	16
3	Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma. <i>Matrix Biology</i> , 2022, 111, 207-225.	3.6	9
4	Multiplex RNA-based detection of clinically relevant <i>MET</i> alterations in advanced non-small cell lung cancer. <i>Molecular Oncology</i> , 2021, 15, 350-363.	4.6	17
5	Neoadjuvant treatment of stage IIIA-N2 in EGFR-Mutant/ALK-rearranged non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 607-621.	2.8	9
6	Multiplex Detection of Clinically Relevant Mutations in Liquid Biopsies of Cancer Patients Using a Hybridization-Based Platform. <i>Clinical Chemistry</i> , 2021, 67, 554-563.	3.2	12
7	BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100113.	1.1	4
8	Molecular characterization of advanced non-small cell lung cancer patients by cfDNA analysis: experience from routine laboratory practice. <i>Journal of Thoracic Disease</i> , 2021, 13, 1658-1670.	1.4	4
9	Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3631-3642.	6.4	6
10	EBUS-TBNA Cytological Samples for Comprehensive Molecular Testing in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 2084.	3.7	21
11	Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS8580-TPS8580.	1.6	1
12	KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8512-8512.	1.6	13
13	Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study. <i>Lung Cancer</i> , 2021, 155, 114-119.	2.0	12
14	MMP1 drives tumor progression in large cell carcinoma of the lung through fibroblast senescence. <i>Cancer Letters</i> , 2021, 507, 1-12.	7.2	33
15	NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment. <i>Molecular Oncology</i> , 2021, 15, 2363-2376.	4.6	16
16	Epigenetic Reprogramming of Tumor-Associated Fibroblasts in Lung Cancer: Therapeutic Opportunities. <i>Cancers</i> , 2021, 13, 3782.	3.7	4
17	Technical Evaluation of the COBAS EGFR Semiquantitative Index (SQI) for Plasma cfDNA Testing in NSCLC Patients with EGFR Exon 19 Deletions. <i>Diagnostics</i> , 2021, 11, 1319.	2.6	3
18	Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1547-1558.	1.1	108

#	ARTICLE	IF	CITATIONS
19	Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Nonâ€“Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, 1351.	7.1	113
20	A Pilot Study to Evaluate Early Predictive Value of Thorax Perfusion-CT in Advanced NSCLC. <i>Cancers</i> , 2021, 13, 5566.	3.7	2
21	Epigenetic <i>SMAD3</i> Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma. <i>Cancer Research</i> , 2020, 80, 276-290.	0.9	25
22	In Search of the Long-Desired â€“Copernican Therapeutic Revolutionâ€™ in Small-Cell Lung Cancer. <i>Drugs</i> , 2020, 80, 241-262.	10.9	12
23	Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. <i>Autoimmunity Reviews</i> , 2020, 19, 102455.	5.8	51
24	Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). <i>Lung Cancer</i> , 2020, 150, 62-69.	2.0	15
25	GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients. <i>Lung Cancer</i> , 2020, 148, 48-54.	2.0	18
26	Capmatinib in <i>MET</i> Exon 14â€“Mutated or <i>MET</i> -Amplified Nonâ€“Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 944-957.	27.0	542
27	Prospective Evaluation of Single Nucleotide Variants by Two Different Technologies in Paraffin Samples of Advanced Non-Small Cell Lung Cancer Patients. <i>Diagnostics</i> , 2020, 10, 902.	2.6	1
28	Using biomarkers to determine optimal combinations with immunotherapy (biomarker discovery) Tj ETQq0 0 0 rgBT JOverlock 10 Tf 50	2.4	3
29	Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9008-9008.	1.6	15
30	Usefulness of Two Independent DNA and RNA Tissue-Based Multiplex Assays for the Routine Care of Advanced NSCLC Patients. <i>Cancers</i> , 2020, 12, 1124.	3.7	5
31	ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. <i>Revista Espanola De Patologia</i> , 2020, 53, 140-148.	0.2	0
32	Stromal markers of activated tumor associated fibroblasts predict poor survival and are associated with necrosis in non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 135, 151-160.	2.0	36
33	Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions. <i>Molecular Oncology</i> , 2019, 13, 2633-2645.	4.6	69
34	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Nonâ€“Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2120-2132.	1.1	48
35	Immune-Related Adverse Events and Outcomes in Patients with Advanced Nonâ€“Small Cell Lung Cancer: A Predictive Marker of Efficacy?. <i>Journal of Thoracic Oncology</i> , 2019, 14, 963-967.	1.1	16
36	Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Nonâ€“small-cell Lung Cancer: Implications of FISH-positive Patterns. <i>Clinical Lung Cancer</i> , 2019, 20, e421-e429.	2.6	27

#	ARTICLE	IF	CITATIONS
37	Clinical Benefit From BRAF/MEK Inhibition in a Double Non-V600E BRAF Mutant Lung Adenocarcinoma: A Case Report. <i>Clinical Lung Cancer</i> , 2019, 20, e219-e223.	2.6	15
38	CMET-22. CAPMATINIB (INC280) IN MET ^T EX14-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): EFFICACY DATA FROM THE PHASE 2 GEOMETRY MONO-1 STUDY. <i>Neuro-Oncology</i> , 2019, 21, vi56-vi56.	1.2	7
39	SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 3-17.	2.4	110
40	Capmatinib (INC280) in MET ^T ex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. <i>Journal of Clinical Oncology</i> , 2019, 37, 9004-9004.	1.6	94
41	PD-L1 expression testing in non-small cell lung cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876349.	3.2	120
42	Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. <i>Cancer Treatment Reviews</i> , 2018, 64, 21-29.	7.7	37
43	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. <i>Journal of Thoracic Disease</i> , 2018, 10, S1516-S1533.	1.4	57
44	EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP). <i>Targeted Oncology</i> , 2018, 13, 621-629.	3.6	24
45	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. <i>Cancer Treatment Reviews</i> , 2018, 71, 47-58.	7.7	37
46	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 771-781.	10.7	167
47	Prospective analysis of liquid biopsies of advanced non-small cell lung cancer patients after progression to targeted therapies using GeneReader NGS platform. <i>Translational Cancer Research</i> , 2018, 8, S3-S15.	1.0	3
48	Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients. <i>Clinical Chemistry</i> , 2017, 63, 751-760.	3.2	62
49	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	10.7	172
50	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017, 77, 3540-3550.	0.9	327
51	Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP). <i>Targeted Oncology</i> , 2017, 12, 513-523.	3.6	21
52	Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib. <i>Journal of Thoracic Oncology</i> , 2017, 12, e78-e80.	1.1	27
53	MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S393-S394.	1.1	20
54	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. <i>Lung Cancer</i> , 2017, 108, 154-160.	2.0	18

#	ARTICLE	IF	CITATIONS
55	Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions. <i>Annals of Oncology</i> , 2017, 28, 2248-2255.	1.2	95
56	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	128
57	Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients. <i>British Journal of Cancer</i> , 2017, 117, 1128-1138.	6.4	45
58	Tyrosine kinase inhibitor combination therapy in first-line treatment of non-small-cell lung cancer: systematic review and network meta-analysis. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2473-2482.	2.0	42
59	Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab. <i>Anticancer Research</i> , 2017, 37, 6429-6436.	1.1	10
60	O.01: Acquired Resistance to EGFR-TKIs in EGFR-Mutant Lung Adenocarcinoma Among Hispanics (RBIOP-CLICaP). <i>Journal of Thoracic Oncology</i> , 2016, 11, S168.	1.1	1
61	P1.03: Utility of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S181-S182.	1.1	1
62	Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 427-437.	5.6	139
63	miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers. <i>Clinical and Translational Oncology</i> , 2016, 18, 153-159.	2.4	24
64	GEOMETRY duo-1: A phase (Ph) Ib/II, multicenter trial of oral cMET inhibitor capmatinib (INC280) ± erlotinib vs platinum + pemetrexed in adult patients (pts) with epidermal growth factor receptor (EGFR)-mutated, cMET-amplified, locally advanced/metastatic non-small cell lung cancer (NSCLC) with acquired resistance to prior EGFR tyrosine kinase inhibitor (TKI) therapy.. <i>Journal of Clinical Oncology</i> , 2016, 34, TPS9109-TPS9109.	1.6	3
65	Heterotypic paracrine signaling drives fibroblast senescence and tumor progression of large cell carcinoma of the lung. <i>Oncotarget</i> , 2016, 7, 82324-82337.	1.8	17
66	BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations. <i>Oncotarget</i> , 2016, 7, 68933-68942.	1.8	26
67	<i>ROS1</i> copy number alterations are frequent in non-small cell lung cancer. <i>Oncotarget</i> , 2016, 7, 8019-8028.	1.8	24
68	Interstitial Lung Disease Arising From Erlotinib Treatment in a Caucasian Patient. <i>Clinical Lung Cancer</i> , 2015, 16, e1-e3.	2.6	8
69	Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149.	7.1	224
70	Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors. <i>Future Oncology</i> , 2015, 11, 1245-1257.	2.4	66
71	Aberrant DNA methylation in non-small cell lung cancer-associated fibroblasts. <i>Carcinogenesis</i> , 2015, 36, bgv146.	2.8	84
72	Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. <i>Future Oncology</i> , 2015, 11, 267-277.	2.4	17

#	ARTICLE	IF	CITATIONS
73	Matrix Stiffening and α 1 Integrin Drive Subtype-Specific Fibroblast Accumulation in Lung Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 161-173.	3.4	44
74	Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies. <i>Cancer Treatment Reviews</i> , 2015, 41, 27-34.	7.7	63
75	Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1816-1820.	1.1	23
76	Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome. <i>Cancer Treatment Reviews</i> , 2014, 40, 723-729.	7.7	19
77	Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: A new era begins. <i>Cancer Treatment Reviews</i> , 2014, 40, 93-101.	7.7	120
78	Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. <i>Annals of Oncology</i> , 2014, 25, 2147-2155.	1.2	27
79	Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. <i>Expert Opinion on Biological Therapy</i> , 2014, 14, 15-26.	3.1	17
80	Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. <i>Lung Cancer</i> , 2014, 84, 161-167.	2.0	81
81	Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors. <i>Cancer Treatment Reviews</i> , 2014, 40, 990-1004.	7.7	70
82	A phase II/III randomized trial of two doses of MK-3475 versus docetaxel in previously treated subjects with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8124-TPS8124.	1.6	1
83	Open, phase II randomized trial of gefitinib alone versus olaparib (AZD2281) plus gefitinib in advanced non-small cell lung cancer (NSCLC) patients (P) with epidermal growth factor receptor (EGFR) mutations: Spanish Lung Cancer Group trial (NCT=1513174/GECP-GOAL).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8127-TPS8127.	1.6	3
84	Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. <i>PLoS ONE</i> , 2014, 9, e107200.	2.5	58
85	Diarrhea associated with afatinib: an oral ErbB family blocker. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 729-736.	2.4	98
86	Treatment strategies after failure to reversible tyrosine kinase inhibitors (rTKI) in EGFR mutant (mut) non-small cell lung cancer (NSCLC) patients (p): A retrospective analysis of 41 Spanish p.. <i>Journal of Clinical Oncology</i> , 2013, 31, e19089-e19089.	1.6	0
87	Sleeve lobectomy after induction chemoradiotherapy. <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 41, 1052-1058.	1.4	31
88	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	10.7	4,943
89	Integrin-Specific Mechanoresponses to Compression and Extension Probed by Cylindrical Flat-Ended AFM Tips in Lung Cells. <i>PLoS ONE</i> , 2012, 7, e32261.	2.5	31
90	Differential progression-free survival (PFS) to erlotinib according to EGFR exon 19 deletion type in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 7540-7540.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations. <i>Clinical Cancer Research</i> , 2011, 17, 1160-1168.	7.0	292
92	Determining the appropriate sleeve lobectomy versus pneumonectomy ratio in central non-small cell lung cancer patients: an audit of an aggressive policy of pneumonectomy avoidance. <i>European Journal of Cardio-thoracic Surgery</i> , 2011, 39, 352-359.	1.4	57
93	Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer. <i>Cancer Management and Research</i> , 2010, 2, 143.	1.9	19
94	Incidence of occult mediastinal node involvement in cNO non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. <i>European Journal of Cardio-thoracic Surgery</i> , 2010, 37, 1168-1174.	1.4	77
95	Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 958-967.	27.0	2,213
96	Wood-Smoke Exposure (WSE) as a Predictor of Response and Survival in Erlotinib-Treated Non-small Cell Lung Cancer (NSCLC) Patients. <i>Journal of Thoracic Oncology</i> , 2009, 4, 142-143.	1.1	4
97	Customized Treatment in Non-Small-Cell Lung Cancer Based on EGFR Mutations and BRCA1 mRNA Expression. <i>PLoS ONE</i> , 2009, 4, e5133.	2.5	153
98	BRCA1: A New Genomic Marker for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2008, 9, 331-339.	2.6	44
99	Translational research in glioblastoma multiforme: molecular criteria for patient selection. <i>Future Oncology</i> , 2008, 4, 219-228.	2.4	16
100	A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1224-1235.	1.1	106
101	Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. <i>Biochemical and Biophysical Research Communications</i> , 2006, 342, 1228-1232.	2.1	88
102	Predicting the outcome of chemotherapy for lung cancer. <i>Current Opinion in Pharmacology</i> , 2006, 6, 323-331.	3.5	68
103	Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going. <i>Current Opinion in Oncology</i> , 2006, 18, 135-143.	2.4	35
104	Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. <i>Cancer Cell</i> , 2006, 10, 39-50.	16.8	348
105	Future Directions in the Second-Line Treatment of Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2006, 33, 45-51.	2.2	9
106	Epidermal Growth Factor Receptor Activation: How Exon 19 and 21 Mutations Changed Our Understanding of the Pathway. <i>Clinical Cancer Research</i> , 2006, 12, 7222-7231.	7.0	84
107	Blockade of Wnt-1 signaling induces apoptosis in human colorectal cancer cells containing downstream mutations. <i>Oncogene</i> , 2005, 24, 3054-3058.	5.9	210
108	Wnt Signaling in Stem Cells and Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, 54-60.	2.6	58

#	ARTICLE	IF	CITATIONS
109	Efficacy of Wnt-1 monoclonal antibody in sarcoma cells. <i>BMC Cancer</i> , 2005, 5, 53.	2.6	48
110	Wnt2 as a new therapeutic target in malignant pleural mesothelioma. <i>International Journal of Cancer</i> , 2005, 117, 326-332.	5.1	78
111	Crossing the rubicon in lung adenocarcinoma: the conundrum of EGFR tyrosine kinase mutations. <i>Future Oncology</i> , 2005, 1, 319-322.	2.4	0
112	The role of Wnt signaling in cancer and stem cells. <i>Future Oncology</i> , 2005, 1, 787-797.	2.4	65
113	Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer. <i>Lung Cancer</i> , 2005, 50, 25-33.	2.0	74
114	Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. <i>Cancer Research</i> , 2005, 65, 743-8.	0.9	88
115	An Anti-Wnt-2 Monoclonal Antibody Induces Apoptosis in Malignant Melanoma Cells and Inhibits Tumor Growth. <i>Cancer Research</i> , 2004, 64, 5385-5389.	0.9	196
116	Wnt Inhibitory Factor-1 Is Silenced by Promoter Hypermethylation in Human Lung Cancer. <i>Cancer Research</i> , 2004, 64, 4717-4720.	0.9	272
117	Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. <i>Oncogene</i> , 2004, 23, 6170-6174.	5.9	248
118	Molecular predictors of response to chemotherapy in lung cancer. <i>Seminars in Oncology</i> , 2004, 31, 20-27.	2.2	70
119	Cloning and characterization of the promoter of human Wnt inhibitory factor-1. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 229-234.	2.1	41
120	Dickkopf-1 antagonizes Wnt signaling independent of β^2 -catenin in human mesothelioma. <i>Biochemical and Biophysical Research Communications</i> , 2004, 323, 1246-1250.	2.1	118
121	Tyrosinase mRNA in Blood of Patients With Melanoma Treated With Adjuvant Interferon. <i>Journal of Clinical Oncology</i> , 2002, 20, 4032-4039.	1.6	53
122	DNA repair and cisplatin resistance in non-small-cell lung cancer. <i>Lung Cancer</i> , 2002, 38, 217-227.	2.0	166
123	Liver metastases in colorectal cancer. Reply to figueras et al. , 2001, 3, 280-280.		0